- Home
- IGI vs PRLD Comparison
IGI vs PRLD Comparison
Compare IGI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGI
- PRLD
- Stock Information
- Founded
- IGI 2009
- PRLD 2016
- Country
- IGI United States
- PRLD United States
- Employees
- IGI N/A
- PRLD N/A
- Industry
- IGI Investment Managers
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- IGI Finance
- PRLD Health Care
- Exchange
- IGI Nasdaq
- PRLD Nasdaq
- Market Cap
- IGI 190.2M
- PRLD 110.0M
- IPO Year
- IGI N/A
- PRLD 2020
- Fundamental
- Price
- IGI $17.18
- PRLD $1.92
- Analyst Decision
- IGI
- PRLD Buy
- Analyst Count
- IGI 0
- PRLD 3
- Target Price
- IGI N/A
- PRLD $5.33
- AVG Volume (30 Days)
- IGI 33.9K
- PRLD 231.0K
- Earning Date
- IGI 01-01-0001
- PRLD 10-30-2024
- Dividend Yield
- IGI 4.79%
- PRLD N/A
- EPS Growth
- IGI N/A
- PRLD N/A
- EPS
- IGI N/A
- PRLD N/A
- Revenue
- IGI N/A
- PRLD N/A
- Revenue This Year
- IGI N/A
- PRLD N/A
- Revenue Next Year
- IGI N/A
- PRLD N/A
- P/E Ratio
- IGI N/A
- PRLD N/A
- Revenue Growth
- IGI N/A
- PRLD N/A
- 52 Week Low
- IGI $15.13
- PRLD $1.66
- 52 Week High
- IGI $17.79
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- IGI 32.06
- PRLD 30.18
- Support Level
- IGI $17.16
- PRLD $1.87
- Resistance Level
- IGI $17.32
- PRLD $2.01
- Average True Range (ATR)
- IGI 0.17
- PRLD 0.12
- MACD
- IGI -0.04
- PRLD 0.10
- Stochastic Oscillator
- IGI 10.28
- PRLD 29.41
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.